EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

The Current and Future of Biomarkers of Immune Related Adverse Events

William Bracamonte-Baran, Sang T Kim

Rheumatic Disease Clinics of North America · 2024-05 · 50 (2) · 201-227

DOI: 10.1016/j.rdc.2024.01.004 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Rheumatic Disease Clinics of North America, 2024-05. Verfasst von William Bracamonte-Baran und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, Allergy & Immunology, Yale University, 300 Cedar Street, TAC S541, New Haven, CT 06520, USA. Hauptthemen laut MEDLINE: Biomarkers, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 140 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAMS NIH HHS, Rheumatology Research Foundation Fund, Rheumatology Research Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

With their groundbreaking clinical responses, immune checkpoint inhibitors (ICIs) have ushered in a new chapter in cancer therapeutics. However, they are often associated with life-threatening or organ-threatening autoimmune/autoinflammatory phenomena, collectively termed immune-related adverse events (irAEs). In this review, we will first describe the mechanisms of action of ICIs as well as irAEs. Next, we will review biomarkers for predicting the development of irAEs or stratifying risks.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BiomarkersImmune Checkpoint InhibitorsHumansAutoimmune DiseasesNeoplasms

Stichwörter der Autor:innen

AutoantibodiesChemokinesCytokinesImmune checkpoint-inhibitorsImmune-related adverse eventsMicrobiome

Substanzen

BiomarkersImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Rheumatology, Allergy & Immunology, Yale University, 300 Cedar Street, TAC S541, New Haven, CT 06520, USA.
  • Department of Rheumatology, Allergy & Immunology, Yale University, 300 Cedar Street, TAC S541, New Haven, CT 06520, USA. Electronic address: sangtaek.kim@yale.edu.

Förderung

  • NIAMS NIH HHS
  • Rheumatology Research Foundation Fund
  • Rheumatology Research Foundation
  • National Institutes of Health

Zitieren

APA

Bracamonte-Baran, W., & Kim, S. T. (2024). The Current and Future of Biomarkers of Immune Related Adverse Events. Rheumatic Disease Clinics of North America, 50(2), 201-227. https://doi.org/10.1016/j.rdc.2024.01.004

Vancouver

Bracamonte-Baran W, Kim ST. The Current and Future of Biomarkers of Immune Related Adverse Events. Rheumatic Disease Clinics of North America. 2024;50(2):201-227. doi:10.1016/j.rdc.2024.01.004

BibTeX
@article{BracamonteBaran2024,
  author = {Bracamonte-Baran, William and Kim, Sang T},
  title = {The Current and Future of Biomarkers of Immune Related Adverse Events},
  journal = {Rheumatic Disease Clinics of North America},
  year = {2024},
  volume = {50},
  number = {2},
  pages = {201--227},
  doi = {10.1016/j.rdc.2024.01.004}
}
Kostenlos starten →